Literature DB >> 20184972

Cell-specific inhibition of p38alpha as a therapeutic strategy for inflammatory bowel disease.

Eóin N McNamee, Colm B Collins, Matthew D P Lebsack, Jesús Rivera-Nieves.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20184972      PMCID： PMC4414012          DOI： 10.1053/j.gastro.2010.02.030

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  22 in total

1.  Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease.

Authors:  Daan Hommes; Bernt van den Blink; Terry Plasse; Joep Bartelsman; Cuiping Xu; Bret Macpherson; Guido Tytgat; Mailkel Peppelenbosch; Sander Van Deventer
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

Review 2.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases.

Authors:  Sanjay Kumar; Jeffrey Boehm; John C Lee
Journal:  Nat Rev Drug Discov       Date:  2003-09       Impact factor: 84.694

3.  Patterns of cell proliferation in gastrointestinal disease.

Authors:  B Bell; E Deschner; T P Almy; M Lipkin
Journal:  Dis Colon Rectum       Date:  1967 Mar-Apr       Impact factor: 4.585

4.  p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease.

Authors:  Georg H Waetzig; Dirk Seegert; Philip Rosenstiel; Susanna Nikolaus; Stefan Schreiber
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

5.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.

Authors:  S Schreiber; R N Fedorak; O H Nielsen; G Wild; C N Williams; S Nikolaus; M Jacyna; B A Lashner; A Gangl; P Rutgeerts; K Isaacs; S J van Deventer; J C Koningsberger; M Cohard; A LeBeaut; S B Hanauer
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

Review 6.  p38 MAP kinase inhibitors: many are made, but few are chosen.

Authors:  Celia Dominguez; David A Powers; Nuria Tamayo
Journal:  Curr Opin Drug Discov Devel       Date:  2005-07

Review 7.  Interleukin-17 family members and inflammation.

Authors:  Jay K Kolls; Anders Lindén
Journal:  Immunity       Date:  2004-10       Impact factor: 31.745

8.  Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis.

Authors:  Longsheng Zuo; Zhen Huang; Lei Dong; Lingqing Xu; Yi'an Zhu; Ke Zeng; Chenyu Zhang; Jiangning Chen; Junfeng Zhang
Journal:  Gut       Date:  2009-12-01       Impact factor: 23.059

Review 9.  p38 pathway kinases as anti-inflammatory drug targets.

Authors:  J F Schindler; J B Monahan; W G Smith
Journal:  J Dent Res       Date:  2007-09       Impact factor: 6.116

10.  Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor.

Authors:  Johanna Westra; Berber Doornbos-van der Meer; Peter de Boer; Miek A van Leeuwen; Martin H van Rijswijk; Pieter C Limburg
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156
View more
  2 in total

1.  Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis.

Authors:  Paolo Biancheri; Martyn R Foster; Matthew C T Fyfe; Thomas T MacDonald; Sameer Sirohi; Yemisi Solanke; Eleanor Wood; Adele Rowley; Steve Webber; Claire A Walshe
Journal:  Inflamm Bowel Dis       Date:  2016-06       Impact factor: 5.325

2.  Mapk14 is a Prognostic Biomarker and Correlates with the Clinicopathological Features and Immune Infiltration of Colorectal Cancer.

Authors:  Dan Wang; Li Peng; Li Hua; Jiaxiang Li; Yifei Liu; Yanhong Zhou
Journal:  Front Cell Dev Biol       Date:  2022-01-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.